Ulcerative Colitis | Current Treatment | EU5 | 2024

Many well-established therapies are available to treat ulcerative colitis (UC) in the EU5. TNF-alpha inhibitors (Janssen’s Remicade, AbbVie’s Humira), a CAM inhibitor (Takeda’s Entyvio), and an IL-12/23 inhibitor (Janssen’s Stelara) are the most widely used biologics for moderate to severe UC and are entrenched as first-line biologics. In addition, several new therapies, including JAK inhibitors (Pfizer’s Xeljanz, AbbVie’s Rinvoq, and Alfasigma’s Jyseleca), an IL-23 inhibitor (Eli Lilly’s Omvoh), S1P-R modulators (BMS’s Zeposia and Pfizer’s Velsipity), and biosimilars of infliximab and adalimumab have been approved for UC in Europe in the past few years. The availability of agents from different drug classes and the launch of biosimilars not only expand treatment options but also influence physicians’ prescribing behavior and thus the treatment landscape.

Questions Answered:

• Which drug classes are the patient-share leaders in each line of therapy? How are the various biological agents positioned in surveyed physicians’ UC treatment algorithm?
• What are the most influential drivers of treatment selection, and under which scenarios do/will physicians prescribe Zeposia and Rinvoq?
• What are the common treatment scenarios before initiating each targeted therapy (i.e., Remicade, Humira, Simponi, Stelara, Entyvio, Rinvoq, Xeljanz, Jyseleca, Zeposia, biosimilar infliximab, and biosimilar adalimumab)?
• What factors drive therapy discontinuation and switching? What factors have/will drive recent/anticipated prescribing changes?

Markets covered: France, Germany, Italy, Spain, and United Kingdom

Primary research: 250 gastroenterologists completed the survey. Of these physicians, 50 were in France, 50 in Germany, 50 in Italy, 50 in Spain, and 50 in the United Kingdom. The survey was fielded in March 2024.

Key companies: Johnson & Johnson Innovative Medicine, AbbVie, Takeda, Eli Lilly, Pfizer, others

Key drugs: Humira, Remicade, Entyvio, Xeljanz, Stelara, Zeposia, Rinvoq, Jyseleca, adalimumab biosimilars, infliximab biosimilars

Product Description: Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.